191 related articles for article (PubMed ID: 35642015)
1. Cost-effectiveness analysis of olanzapine in four-drug antiemetic therapy in Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy.
Kondo Y; Tachi T; Sakakibara T; Kato J; Mizuno T; Miyake Y; Teramachi H
J Pharm Health Care Sci; 2022 Jun; 8(1):15. PubMed ID: 35642015
[TBL] [Abstract][Full Text] [Related]
2. Comparative Cost-utility Analysis Between Aprepitant- and Fosaprepitant-containing Regimens To Prevent Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan.
Kashiwa M; Matsushita R
Clin Ther; 2019 May; 41(5):929-942. PubMed ID: 31036286
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan.
Kashiwa M; Matsushita R
BMC Health Serv Res; 2019 Jul; 19(1):438. PubMed ID: 31262292
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy.
Tsukiyama I; Hasegawa S; Ikeda Y; Takeuchi M; Tsukiyama S; Kurose Y; Ejiri M; Sakuma M; Saito H; Arakawa I; Inoue T; Yamaguchi E; Kubo A
Cancer Sci; 2018 Sep; 109(9):2881-2888. PubMed ID: 29999572
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.
Chanthawong S; Lim YH; Subongkot S; Chan A; Andalusia R; Ahmad Bustamam RS; Chaiyakunapruk N
Support Care Cancer; 2019 Mar; 27(3):1109-1119. PubMed ID: 30112718
[TBL] [Abstract][Full Text] [Related]
6. Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial).
Shimizu H; Suzuki K; Uchikura T; Tsuji D; Yamanaka T; Hashimoto H; Goto K; Matsui R; Seki N; Shimada T; Ikeda S; Ikegami N; Hama T; Yamamoto N; Sasaki T
J Pharm Health Care Sci; 2018; 4():31. PubMed ID: 30555710
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine cost-effectiveness in vomiting and nausea from highly emetogenic chemotherapy in children and adolescents.
Sra MS; Ganguly S; Naik RD; Sasi A; Sharma P; Giri RK; Abdul Rasheed A; Bakhshi S
BMJ Support Palliat Care; 2024 Jan; 13(e3):e1272-e1279. PubMed ID: 36813535
[TBL] [Abstract][Full Text] [Related]
8. Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong.
Chan SL; Jen J; Burke T; Pellissier J
Asia Pac J Clin Oncol; 2014 Mar; 10(1):80-91. PubMed ID: 24571059
[TBL] [Abstract][Full Text] [Related]
9. Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis.
Xu X; Bao Y; Xu K; Zhang Z; Zhao N; Li X
Front Public Health; 2022; 10():913129. PubMed ID: 35903377
[TBL] [Abstract][Full Text] [Related]
10. Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer.
Kashiwa M; Matsushita R
Int J Clin Pharm; 2023 Aug; 45(4):875-883. PubMed ID: 37079225
[TBL] [Abstract][Full Text] [Related]
11. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
Nakashima K; Murakami H; Yokoyama K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Nishiyama F; Kikugawa M; Kaneko M; Iwamoto Y; Koizumi S; Mori K; Isobe T; Takahashi T
Jpn J Clin Oncol; 2017 Sep; 47(9):840-843. PubMed ID: 28633504
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients.
Chow R; Chiu L; Herrstedt J; Aapro M; Lock M; DeAngelis C; Navari RM
Support Care Cancer; 2021 Aug; 29(8):4269-4275. PubMed ID: 33409724
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Hashimoto H; Abe M; Tokuyama O; Mizutani H; Uchitomi Y; Yamaguchi T; Hoshina Y; Sakata Y; Takahashi TY; Nakashima K; Nakao M; Takei D; Zenda S; Mizukami K; Iwasa S; Sakurai M; Yamamoto N; Ohe Y
Lancet Oncol; 2020 Feb; 21(2):242-249. PubMed ID: 31838011
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan.
Kondo Y; Tachi T; Sakakibara T; Kato J; Kato A; Mizuno T; Miyake Y; Teramachi H
Support Care Cancer; 2022 Aug; 30(8):6775-6783. PubMed ID: 35524869
[TBL] [Abstract][Full Text] [Related]
15. Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy.
Langer J; Wolden ML; Shimoda S; Sato M; Araki E
Diabetes Ther; 2019 Aug; 10(4):1347-1356. PubMed ID: 31168694
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of nirmatrelvir/ritonavir for high-risk adult outpatients with COVID-19 in Japan.
Mizuno T; Kondo Y; Sakai M; Saneyasu K; Kojima R; Miyake Y
J Infect Chemother; 2024 Aug; 30(8):716-724. PubMed ID: 38325626
[TBL] [Abstract][Full Text] [Related]
17. Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan.
Kashiwa M; Matsushita R
Biol Pharm Bull; 2022; 45(7):895-903. PubMed ID: 35786597
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of aprepitant for patients who truly need it in Japan.
Tsukiyama I; Ando M; Tsukiyama S; Takeuchi M; Ejiri M; Kurose Y; Saito H; Arakawa I; Inoue T; Yamaguchi E; Kubo A
Support Care Cancer; 2019 Oct; 27(10):3749-3758. PubMed ID: 30710243
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK.
Humphreys S; Pellissier J; Jones A
Cancer Manag Res; 2013; 5():215-24. PubMed ID: 23950658
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting.
Halloush S; Alhifany AA; Alkhatib NS; Al Bawab AQ; Al-Qawasmeh B; Al Shawakri E; Koeller J
Curr Med Res Opin; 2022 Apr; 38(4):571-577. PubMed ID: 35068277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
